- Company
- AbbVie’s Aquipta becomes the first oral CGRP migraine drug
- by Son, Hyung-Min May 13, 2024 05:52am
- For the first time, an oral CGRP drug has been introduced for the treatment of migraine. AbbVie’s Aquipta has shown positive results as a preventive treatment for chronic migraine as well as episodic migraine in patients who have failed up to 4 prior oral preventive treatments. Experts believe that the benefits of being an oral formulation
- Company
- BeiGene reapplies for Tevimbra’s reimb in esophageal cancer
- by Eo, Yun-Ho May 13, 2024 05:52am
- BeiGene is again attempting reimbursement for its immunotherapy, ‘Tevimbra (tislelizumab)’ in Korea. According to industry sources, BeiGene Korea recently submitted an application for the reimbursement of its Tevimbra (tiselizumab) and is waiting for the Health Insurance Review and Assessment Service's Cancer Disease Review Committee’s
- Company
- MM drug Tecvayli can be prescribed in tertiary hospitals
- by Eo, Yun-Ho May 13, 2024 05:52am
- The new multiple myeloma drug ‘Tecvayli’ can now be prescribed in tertiary hospitals in Korea. According to industry sources, Janssen Korea’s multiple myeloma drug Tecvayli (teclistamab) has passed the drug committee (DC) review of top tertiary hospitals in Korea, including Samsung Medical Center, Seoul National University Hospital, Se
- Company
- Pharma companies showcase their R&D achievements
- by Son, Hyung-Min May 13, 2024 05:52am
- Pharmaceutical companies have disclosed the development outcomes of the obesity treatments, which have now become the trending R&D. As obesity treatments of the GLP-1 class, such as those of Novo Nordisk and Lilly, become blockbuster new drugs globally, the development of latecomers is on the rise. Major companies plan to develop the next-
- Company
- Hanmi’s 2 new accounts of the pipeline enter clinical trial
- by Son, Hyung-Min May 13, 2024 05:51am
- Hanmi Pharm is accelerating the development of new obesity drugs. Following efpeglenatide, which has entered the Phase 3 trial in South Korea, Hanmi Pharm’s other new drug candidate has entered the full-scale clinical trial. Furthermore, Hanmi Pharm plans to establish various pipelines, including an oral agent, digital therapy related to obesit
- Company
- HSF therapy 'Altuviiio' receives Orphan Drug designation
- by Eo, Yun-Ho May 10, 2024 04:33pm
- 'Altuviiio,' a once-weekly administered hemophilia A new drug, has been designated as Korea’s Orphan Drug. The Ministry of Food and Drug Safety (MFDS) announced this in a recent posting. Sanofi-Aventis Korea’s Altuviiio (efanesoctocog alfa) is a first-in-class high sustained factor (HSF) therapy for hemophilia A. With once-weekly
- Company
- Dong-A ST will exclusively supply surgical robot Versius
- by Son, Hyung-Min May 10, 2024 05:47am
- Dong-A ST announced on the 8th that it has signed an agreement with CMR Surgical for the exclusive supply and distribution of the surgical robot ‘Versius’ in Korea. Versius was developed by CMR Surgical, a British company specializing in surgical robots. It has the advantage of having small,&160;modular, and portable robot arms. It can
- Company
- 98% relapse-free Soliris is reimbursed for NMOSD in Korea
- by Son, Hyung-Min May 10, 2024 05:47am
- A new treatment option has been introduced for patients with neuromyelitis optica spectrum disorder (NMOSD), a disease that has over a 90% relapse rate. Soliris became fully reimbursable for NMOSD last month, recording a 98% relapse-free rate. However, there are concerns that the stringent reimbursement requirements for Soliris may reduce pa
- Company
- Korean AI-driven drug discovery speeds up
- by Nho, Byung Chul May 10, 2024 05:46am
- AI-driven new drug discovery through data collaboration among the biopharmaceutical industry, medical institutions, research institutions, universities, and public institutions has accelerated and gained significant attention. Previously, individual biopharmaceutical companies in South Korea conducted AI-driven new drug discovery throug
- Company
- 'Lixiana' dominates the DOAC market in KOR
- by Kim, Jin-Gu May 9, 2024 05:53am
- Daiichi Sankyo Korea’s 'Lixiana (edoxaban)' continues to dominate the market for Direct Oral Anti-Coagulant (DOAC). BMS’s 'Eliquis (apixaban)' sales have recently experienced a slowdown, and Bayer’s 'Xarelto (rivaroxaban)' prescription performance significantly dropped after the generic launch. The sales of Xarelto generic nearly cha
